Heat-Processed Foods Linked to Metabolic Disease

Published Online: Thursday, September 13, 2012
Follow Pharmacy_Times:
Scientists recently determined that increased exposure to methyl-glyoxal (MG), an advanced glycation byproduct that is produced when food is cooked with dry heat, promotes the development of increased abdominal fat, increased insulin resistance, and type 2 diabetes.

Cooking methods that are considered “dry heat” include roasting, grilling, broiling, and baking.

Researchers from Mount Sinai School of Medicine analyzed a group of mice fed a diet high in MG and compared the group with a control over 4 generations. Both diets had the same amount of calories and fat.

Mice that ate MG displayed a deficiency on protective mechanisms over the study period, and the extra abdominal fat they gained produced more inflammatory cytokines. In turn, the unregulated cytokines impaired glucose metabolism in this group.

“The study demonstrates how the prolonged ingestion of seemingly innocuous substances common in human food, such as MG, can reduce defenses and compromise native resistance to metabolic and other diseases,” said lead author Helen Vlassara, MD, director of the Division of Experimental Diabetes and Aging. “Thus far, our findings reflect the need for a dramatic departure from standard clinical recommendations, which should now include a reduction in the amount of dry heat and processed foods in the diet.”


Related Articles
In light of misrepresented statistics and overstated fears about statin-related adverse events, here are 3 of the biggest myths your patients may have heard about these life-saving medications—and the facts
Beyond working in traditional retail, community, and health-system settings, pharmacy students have a lot of options. Two Roosevelt University pharmacy students are proof of that.
Sanofi has announced the FDA approval of its insulin glargine injection (Toujeo), a once-daily long-acting basal insulin, for the improvement of glycemic control in adults with type 1 and type 2 diabetes.
Novo Nordisk has positive results from a completed phase 2 trial on the oral formulation of its investigational, long-acting human glucagon-like peptide-1 analogue.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$